2023-09-05 07:10:57 ET
More on Genmab, Seagen, etc.
- Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors
- Genmab Is Down To Attractive Levels
- Genmab A/S ( GMAB ) Q2 2023 Earnings Call Transcript
- Genmab: Epkinly's Approval Not Big Enough Needle-Mover (Neutral)
- Seagen Tukysa combo breast cancer treatment successful in phase 3
- Genmab raises FY 2023 guidance on back of Darzalex sales
- Seagen, Pfizer get second info request from FTC on $43B merger deal
- Seagen pares loss amid report it will get 2nd request from FTC in Pfizer deal
- Pfizer sees second request as likely in FTC's review of Seagen deal - analyst
For further details see:
Seagen, Genmab succeed in Phase 3 trial for cervical cancer therapy